Dr. Charles Leath
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 140
Licensed in Alabama since 1999, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
AL license 22823 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
- Southeast Health Medical Center Dothan, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
- North Mississippi Medical Center, Inc. (366 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 140
- Services billed
- 454
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 134 | 61 |
| Established patient office or other outpatient visit, 30-39 minutes | 68 | 58 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 43 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Birmingham, AL | 54 |
| Gabapentin Other prescribers in Birmingham, AL | 28 |
| Pregabalin Other prescribers in Birmingham, AL | 20 |
| Medroxyprogesterone Acetate Other prescribers in Birmingham, AL | 15 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Birmingham, AL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 22 payments worth $48,690 in total to this clinician.
| Merck Sharp & Dohme LLC | $37,517 |
|---|---|
| GlaxoSmithKline, LLC. | $5,290 |
| Genmab U.S., Inc. | $3,200 |
| AbbVie Inc. | $2,453 |
| Caris Mpi, Inc. | $213 |
| Medical Device Business Services, Inc. | $18.19 |
| Compensation for services other than consulting (speaking, faculty) | $19,840 |
|---|---|
| Travel and Lodging | $17,330 |
| Consulting Fee | $10,800 |
| Food and Beverage | $720 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging travel to Sydney, Australia · in-kind | $15,461 |
| Merck Sharp & Dohme LLC Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $12,160 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Genmab U.S., Inc. Jul 25, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $3,200 |
| GlaxoSmithKline, LLC. Sep 4, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,800 |
| AbbVie Inc. Sep 26, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,400 |
| GlaxoSmithKline, LLC. May 22, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,400 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging travel to Sydney, Australia · in-kind | $1,066 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging travel to Sydney, Australia · in-kind | $478 |
| Merck Sharp & Dohme LLC Dec 8, 2025 | Travel and Lodging travel to Sydney, Australia | $150 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $12,160 |
| Merck Sharp & Dohme LLC Dec 8, 2025 | Travel and Lodging travel to Sydney, Australia | $150 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging travel to Sydney, Australia · in-kind | $15,461 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging travel to Sydney, Australia · in-kind | $1,066 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging travel to Sydney, Australia · in-kind | $478 |
| AbbVie Inc. Sep 26, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,400 |
| GlaxoSmithKline, LLC. Sep 4, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,800 |
| Genmab U.S., Inc. Jul 25, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $3,200 |
| Merck Sharp & Dohme LLC Jun 1, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Chicago, IL | $26.08 |
| GlaxoSmithKline, LLC. May 22, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,400 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Travel and Lodging travel to Bangkok, Thailand | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $63,793 in research payments for these studies, mostly to the institutions running them.
- A phase 1 dose escalation and cohort expansion study of TSR-042, an an
GlaxoSmithKline, LLC. - First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie Inc. · Active, not recruiting · NCT05527184 - A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After …
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.